Ethiopian Airlines Expands Fleet with New Boeing 787 Dreamliner Order to Boost Global Routes 
Nidec Stock Rises After Accounting Probe Report Eases Delisting Concerns 
SpaceX President Gwynne Shotwell Earns $85.8M as IPO Buzz Grows 
China Food Delivery Stocks Dip as Regulators Crack Down on “Ghost Deliveries” 
Huawei Expands Vietnam Presence Through Strategic Partnership with SHB Bank 
Samsung Boosts DRAM Supply to Tesla as AI-Driven Memory Demand Surges 
Indonesia and Toyota Explore $300M Bioethanol Investment to Boost Renewable Energy Goals 
Apple Stock Dips as Tim Cook Steps Down, John Ternus Named Next CEO 
Nvidia Pushes 800V Data Center Power Systems to Boost Efficiency and Cut Costs 
Chinese Robotics Stocks React as Humanoid Robot Marathon Sparks Competition Concerns 
Florida Investigates OpenAI and ChatGPT Over Alleged Role in FSU Shooting 
Jeff Bezos Eyes $10 Billion Funding Round for AI Venture Project Prometheus 
Amazon Expands AI Bet with Up to $25 Billion Investment in Anthropic 
NVIDIA Acquisition Rumors Dismissed by Morgan Stanley as Strategically Flawed 
SK Hynix Launches 192GB SOCAMM2 Memory for Nvidia’s Next-Gen AI Chips 
Rising Jet Fuel Costs from Iran Conflict Push Airfare Higher Across Europe 
Tesla Q1 Earnings Preview: Robotaxi Delays and SpaceX Merger Speculation Grow 
LEXINGTON, Mass., March 07, 2017 -- Curis, Inc. (Nasdaq:CRIS), a biotechnology company focused on the development and commercialization of innovative and effective drug candidates for the treatment of human cancers, today announced that the Company will release its fourth quarter and year-end 2016 financial results on Thursday, March 9, 2017, before the U.S. financial markets open. The Company's management will also host a conference call on the same day at 8:30 a.m. EST, to review its various pipeline programs, including CUDC-907, a dual HDAC/ PI3K inhibitor, CA-170, an oral small molecule antagonist of PD-L1/VISTA and other molecules under collaboration with Aurigene, and its partnered program, Erivedge® (vismodegib). The Company's management will also review its financial results as of and for the fourth quarter and year ended December 31, 2016.
To access the live conference call, please dial (877) 868-1829 from the United States or (253) 237-1135 from other locations, shortly before 8:30 a.m. EST. The conference ID number is 84640331. The conference call can also be accessed on the Curis website at www.curis.com in the Investors section.
About Curis, Inc.
Curis is a biotechnology company focused on the development and commercialization of innovative and effective drug candidates for the treatment of human cancers, including its lead development candidate, CUDC-907, a dual HDAC and PI3K inhibitor that is being investigated in clinical studies in patients with lymphomas and solid tumors. Curis is also engaged in a broad collaboration with Aurigene in the areas of immuno-oncology and precision oncology. As part of this collaboration, Curis has exclusive licenses to oral small molecule antagonists of the PD1 and VISTA pathways, including PDL1/VISTA antagonist CA-170, and oral small molecule antagonists of the PD1 and TIM3 pathways, including PDL1/TIM3 antagonist CA-327, as well as to molecules designed to inhibit the IRAK4 kinase, including CA-4948. CA-170 is currently undergoing testing in a Phase 1 trial in patients with advanced solid tumors and lymphomas. Curis is also party to a collaboration with Genentech, a member of the Roche Group, under which Genentech and Roche are commercializing Erivedge® for the treatment of advanced basal cell carcinoma, and are further developing Erivedge in other diseases including idiopathic pulmonary fibrosis and myelofibrosis.
For more information, visit Curis' website at www.curis.com.
For More Information: James E. Dentzer Chief Financial Officer & Chief Administrative Officer Curis, Inc. 617-503-6500 [email protected] Media Contact: David Schull Russo Partners 212-845-4271 [email protected]
